阅读说明：本技术 用于治疗与肠道微生物组的扰乱的组成或功能有关的病症的益生元 (Prebiotics for the treatment of disorders associated with disturbed composition or function of the gut microbiome ) 是由 鲁德·阿尔伯斯 玛丽亚·祖玛基 于 2018-09-07 设计创作，主要内容包括：本发明涉及益生元组合物,其用于治疗性或预防性治疗对象中的与肠道微生物组的扰乱的组成或功能有关的病症的方法中的用途中,所述用途包括向所述对象口服施用所述益生元组合物,其中所述组合物包含至少0.1重量％的源自果实、胡萝卜、豌豆、菊苣或甜菜的RG-I多糖的干物质,所述RG-I多糖具有超过15kDa的分子量并且具有由半乳糖醛酸残基和鼠李糖残基组成的主链,所述鼠李糖残基包含在α(1→4)-半乳糖醛酸-α(1→2)-鼠李糖残基中,其中所述RG-I多糖中的半乳糖醛酸残基与鼠李糖残基的摩尔比在20:1至1:1的范围内。(The present invention relates to a prebiotic composition, for use in a method for the therapeutic or prophylactic treatment of a disorder in a subject which is associated with a disturbed composition or function of the gut microbiome, the use comprising orally administering the prebiotic composition to the subject, wherein the composition comprises at least 0.1 wt.% dry matter of RG-I polysaccharides originating from fruit, carrots, peas, chicory or sugar beets, the RG-I polysaccharide has a molecular weight of more than 15kDa and has a backbone consisting of galacturonic acid residues and rhamnose residues, the rhamnose residue is contained in the alpha (1 → 4) -galacturonic acid-alpha (1 → 2) -rhamnose residue, wherein the molar ratio of galacturonic acid residues to rhamnose residues in the RG-I polysaccharide is in the range of 20:1 to 1: 1.)